INTRODUCTION AND BACKGROUND WITH LITERATURE REVIEW
Pharmaceutical industry positions and job descriptions are largely unknown to pharmacy students. A recent article showed that pharmacy students are aware of postgraduate training programs, such as fellowships; however, evidence shows students do not receive enough information about industry career opportunities while in pharmacy school (Audette, McGann, Horton, & Silva, 2014; Shpilfogel, Tyrrell, & Alexander, 2015a; Yung, Johal, & Pan, 2004) . Despite a lack of knowledge about career opportunities, the number of fellowship positions fi lled each year has grown signifi cantly. The current number of fellowships occupied by pharmacists is approaching 450-an increase from 250 positions four years prior (Alexander, Dipsia, Wells, & Singh, 2018) . Departments included under fellowships are medical aff airs, regulatory aff airs, clinical research and development, commercial, health outcomes research, and more.
The primary purpose of this article is to describe how a career in industry is benefi cial to a variety of constituents, including patients, health care providers, and students. A secondary purpose is to highlight ten primary industry positions for pharmacists. By detailing a
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personal experience in industry, other pharmacy students can have a better glimpse of a unique career path and what this type of work involves.
METHODOLOGY
The Industry Pharmacist Organization (IPhO), the Rutgers Fellowship Brochure (Rutgers, 2017) , and other sources were utilized to summarize ten pharmaceutical industry positions for pharmacists. Details of the diff erent areas can be found in Table 1 . In addition, depending on the company, some jobs may integrate multiple departments; for example, medical information and medical aff airs positions have multiple similarities.
Departments with the most fellowship positions fi lled by pharmacists as of 2018 are medical aff airs followed by regulatory aff airs . Opportunities, besides those mentioned, within early clinical development include clinical pharmacology and translational medicine. Students with an interest in pharmacokinetics/pharmacodynamics (PK/PD) should look into clinical pharmacology (Goh, Alrawi, & Lozito, 2006) . Translational medicine would involve bench to bedside research integrating both basic science and clinical research aspects. Firsthand experience seems to be the ideal way for pharmacy students to understand industry positions. My own personal experience at Kashiv Pharma, LLC can be seen in the next section.
STUDENT EXPERIENCE
Kashiv Pharma is located in Bridgewater, New Jersey. The company specializes in 505(b)2 products, which is an accelerated approval pathway for reformulations of current drugs. For instance, a product approved, but dosed four times a day, has the potential to be reformulated. Reformulating the product could allow for once-daily dosing and would benefit patients in terms of compliance, better pharmacokinetics, level of effectiveness, or improved safety profile. I will explain my experience from working in the market research or business development sector as a rotation student and intern.
Daily responsibilities included reading clinical trials, utilizing Intercontinental Marketing Services (IMS) data for prescription volume and sales, scanning patents, searching for other drugs in development using a program called PharmaCircle™, and utilizing various other sources. After compiling the information, I would make a document summarizing the data in order to explain the information to other people in the company. Final steps would be to determine whether the product concept was worth pursuing or if it should be abandoned.
Here is an example of how a typical product would be evaluated. Let's call the drug Product X. Product X is currently dosed three to four times per day and has adverse side effects. Using IMS data, the product had 12 million prescriptions written last year and $360 million in sales, which tells us there is a good market for the drug. Next, looking at clinical trial information and the package insert can give us detailed clinical information about the product. Questions to answer include: Answering these questions starts to delineate the product concept, which would give an impression whether Product X is capable of being improved or not.
Some surprising facts can come from a literature review. For instance, a few articles showed that extended release products previously existed for certain medications we were evaluating. The extended release product was even superior to the immediate release, but for unknown reasons, it was discontinued during development or in the post-market phase. If discontinuation occurs, it is important to determine the root cause. Was the profit from the drug not enough to sustain development? Did a company acquire a more important project? These are important questions to ask.
Once clinical trials, IMS data, and package insert data have been scoured, the competitive atmosphere must be evaluated. What other products for the disease state are already on the market or in clinical development? Pharmacircle™ is a database that can show the current stage of development for a medication, which is particularly useful for evaluation of competitors. For example, Pharmacircle™ shows whether a product is in preclinical, clinical trial phases (I-IV), on the market, or has been discontinued. The software also includes links to the websites of the companies that manufacture the drug. Important information from company websites includes news articles or annual reports highlighting the progress of the medication.
In some instances, PharmaCircle™ may show that a drug is still in clinical development. However, the company website may have a recent press release showing negative results of the most recent trial. The assumption is that the drug would likely be discontinued.
Patents help to understand if a certain technology or formulation has already been assessed. For instance, one of the products Kashiv evaluated was initially unstable. An outside researcher came to Kashiv for a partnership, claiming he had invented a technology that gave a stable formulation. He also claimed the formulation was completely novel. After searching patents, it was discovered that two to three other formulations existed and had patents for the same product. Not only were there patents for stable formulations of the drug, but a similar product was already marketed in Germany. The person who came to the company asking for a partnership did not have their own patent at the time.
After data has been gathered from IMS, clinical trials, package inserts, PharmaCircle™, and elsewhere, the next steps could be taken, which involve external assessments of the product concept. These include talking with key opinion leaders (KOLs), submitting surveys to clinicians that use the current medication in practice, and contracting with other market research firms for discussions with pharmacy benefit managers (PBMs). Discussions with PBMs evaluate the likelihood that the new formulation of Product X will be covered by insurance. Talks with KOL's usually involve a phone call to experts in the field. Generally, these are medical doctors who extensively prescribe the medication and may have been involved in published articles covering the drug in question. The phone call is important to understand, from a primary source, how often the medication is used and how the drug compares to other medications for the same indication. Most often, the information the medical doctor gives coincides with the original research; however, if their opinion differs significantly, further evaluation of the literature is necessary. Feedback from multiple physicians is important. Interviewing multiple KOL's will generally give a good trend and help to see if there are outliers.
Market research surveys are sent to physicians. Kashiv uses a contract organization to deliver the surveys to multiple physicians (example n = 25). These surveys generally use Likert scales (ratings of 1-10) to gather information. Criteria assessed for the medication generally include clinical effectiveness, side effects, and how the medication compares to others that treat the same disease state. Eventually, the product concept (Product X) is discussed with the physicians taking the survey. Finally, the physicians evaluate the need for improvement to the current formulation, how they believe reformulating will effect safety and efficacy, whether they think they would prescribe more of the drug after the reformulation, and so forth. Comparing survey data with data from existing clinical trials is important to ensure that the data matches. An example of conflicting evidence includes adverse event reporting in clinical trials differing from the amount of adverse events reported by physicians in the surveys or phone calls.
Another aspect of market research involves discussing the product concept with pharmacy benefit managers (PBMs).
If Product X will not be covered by insurance, the likelihood of the product failing on the market increases. The same company that performs physician surveys is contracted by Kashiv for market research with PBMs. The contract company will usually make phone calls or visits with PBMs to discuss the current product, other medications on the market, and the concept of Product X. The PBM will provide information on which tier the current drug is covered, a forecast for the tier that developed Product X will be placed into, and their estimation for the cost of the product. The data gathered is generally a rough estimate, but it's important to determine w insurance companies will likely think about Product X when the drug is marketed. From personal observation, it seems difficult to get PBMs to see the benefit of once-a-day prescriptions without further evidence. For this reason, clinical trials of 505(b)2 products should aim to prove that Product X will be once a day and that it will improve the effectiveness and/or safety over the current formulation. Table 2 . Review of various tiers according to payer system, most ideal tier for approval would be tier 3. Preferred brands are mostly covered by insurance and take initial precedence in prescription utilization over tiers 4 and 5. Generally, the steps above are the majority of the work done in business development. Next steps include meeting with members of the company to discuss market research data and to determine if Product X is a candidate for further development. If Product X is a good candidate, it will move on to the formulations team. Once a formulation is developed, the medication moves into clinical trials and to market, assuming success at each stage. Since the medication that Product X is based on is already on the market, the development process is generally much shorter than it is for a new chemical entity (NCE). The pathway for improved formulations is called the 505(b)2 pathway by the FDA. For NCEs the pathway follows a 505(b)1 route.
COMMUNITY IMPACT
Industry pharmacists' impact on pharmaceutical development could be largely beneficial to patients in the future. Products that pharmacists in industry develop could reduce pill burden, increase compliance, increase effectiveness, and reduce adverse effects associated with current therapies. By focusing on 505(b)2 products, the timeframe to bring these medications to market is greatly reduced compared to development of an NCE, allowing patients to access the medications sooner. Products evaluated at Kashiv Pharma cover patients in all age ranges so there is a large population that may be positively affected. Working with PBMs can allow for reduced prices of the medications to patients as well.
Improvement to medications not only impacts patients, but also the work of health care providers. Work in industry can profoundly impact health care systems, such as hospitals, long-term care facilities, and so forth. For instance, new medications could affect treatment guidelines for various disease states.
Other people potentially impacted by this article are pharmacy students. By sharing personal rotation and internship experiences, pharmacy students may benefit by having a glimpse into pharmaceutical industry work before having firsthand experiences. In fact, only 20% of current industrial pharmacists completed a fellowship . Many started out as clinicians and transferred to industry or went straight into industry from pharmacy school. Oftentimes fellowships can provide an accelerated track to director roles.
STUDENT IMPACT
Guest speakers and pharmacy school curriculum provide another avenue to learn about the pharmaceutical industry. Industry professionals occasionally come to speak about their work. One article evaluating 193 pharmacy students showed that 30% of students first learned about careers in the pharmaceutical industry from a guest speaker (Shpilfogel, Tyrrell, & Alexander, 2015a) . Other times, pharmacy schools will have electives that students can take to learn more about industry. One ten-week course at the Massachusetts College of Pharmacy and Health Sciences (MCPHS) covering industry showed a significant improvement in first-year pharmacy (P1) students' knowledge across seven functional industry careers. The course improved student industry interest, from only 55% saying they were interested to 70% being interested in an industry career, and from 45% to 75% saying they had a specific area of interest by the end of the class (Audette et al., 2014) .
CONCLUSION
Pharmacists are sought out for their broad clinical and scientific knowledge by pharmaceutical companies. This article touches on many of the different positions available to pharmacists through fellowships. There are several other industry positions besides those mentioned, such as manufacturing. Direct pharmaceutical experience through rotations, internships, or fellowships are important not only for training experiences, but also for building a professional network. In addition, joining pharmaceutical organizations such as IPhO and/or ISPE to meet peers interested in industry helps, as involvement provides multiple networking opportunities. I suggest taking pharmaceutical industry courses to understand more about the career opportunities. I hope my experiences provide a glimpse of responsibilities that a pharmacist may have in industry.
